Welcome to our dedicated page for DR REDDYS LABORATORIES SEC filings (Ticker: RDY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on DR REDDYS LABORATORIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into DR REDDYS LABORATORIES's regulatory disclosures and financial reporting.
Dr. Reddy’s Laboratories (RDY) reported interim results for the quarter and six months ended September 30, 2025. Six‑month revenues were Rs. 173,503 million with profit of Rs. 28,364 million; basic EPS was Rs. 34.30. For the quarter, revenues were Rs. 88,051 million and profit was Rs. 14,268 million.
Gross profit for six months reached Rs. 96,767 million against operating expenses of Rs. 61,779 million, yielding operating profit of Rs. 34,988 million. The effective tax rate was 24.2% for six months. Operating cash flow was Rs. 30,202 million; cash and cash equivalents stood at Rs. 9,906 million with other investments of Rs. 64,487 million.
By segment (six months), Global Generics delivered Rs. 154,118 million revenue; PSAI contributed Rs. 17,631 million. By geography, revenues were United States Rs. 69,958 million, India Rs. 31,781 million, Russia Rs. 15,829 million, and Others Rs. 55,935 million. The balance sheet showed total assets Rs. 542,005 million, equity Rs. 362,082 million, short‑term borrowings Rs. 41,155 million and long‑term borrowings Rs. 17,384 million. The company paid a dividend of Rs. 6,659 million and recorded inventory write‑downs of Rs. 3,450 million over six months.
Amendment No. 6 to Schedule 13D reports ownership and transfer details for DR REDDY'S LABORATORIES LTD ADSs (ticker RDY). On September 17, 2025, G.V. Prasad transferred 96,095,920 post-split shares to GVP Family Trust and K. Satish Reddy transferred 75,630,620 post-split shares to VSD Family Trust for estate planning and family succession. After these transfers, reporting persons may be deemed to beneficially own between approximately 9.07% and 13.58% of outstanding post-split shares depending on constructive ownership through trusts and HUFs. The filing explains source of shares (merger-related distributions, prior transfers, inheritance) and trust deeds that include ROFR and tag-along rights.